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Background. The 50 kD form of the hormone stanniocalcin-
1 (STC50) is widely distributed in organs such as kidney, lung,
and liver. Kidney collecting duct cells produce STC50 for lo-
cal targeting to proximal tubule cells to increase phosphate re-
absorption. As such the current dogma is that in most organs
STC50 is a purely local mediator that is not released into the
circulation. However, liver hepatocytes contain high levels of
both STC50 and its receptor but little evidence of STC produc-
tion, suggesting that the hormone may in fact be delivered to
hepatocytes systemically. Moreover, previous data suggest that
red blood cells may in fact bind STC. In this report, we have
sought to identify STC binding activity in mammalian blood.
Methods. Human, pig, and dog red blood cells were analyzed
in STC receptor binding assays. Mouse red blood cells and adult
mouse kidney were also analyzed histologically for the presence
of STC ligand and receptor.
Results. Saturable, high affinity STC receptors were identified
on red blood cells from all species. More intriguingly, STC bind-
ing activity was also identified in glomerular filtrate, indicative
of a soluble, filterable STC binding protein. This binding pro-
tein was subsequently observed being reabsorbed in proximal
straight tubules.
Conclusion. These findings suggest that our inability to de-
tect STC in mammalian serum is due to its being attached to
soluble and tethered forms of a high-affinity binding protein.
This could be a means of delivering STC to distant targets as
well as a mechanism for removing unwanted hormone from the
circulation.
One of the more intriguing facets of stanniocalcin-1
(STC-1) physiology relates to the nature of the circulating
hormone. The perspective from our laboratory for some
time has been that STC only circulates in females and
only during pregnancy and lactation. This conclusion is
based on the fact that STC has proven to be undetectable
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in the serum of humans and other mammals by radioim-
munoassay. Serum from males and nonpregnant females
is generally incapable of causing significant displacement
of the radioiodinated tracer. We have also been unable to
extract significant amounts of STC from serum using ei-
ther concanavalin A or immunoaffinity chromatography
[1]. During pregnancy and lactation, however, circulat-
ing STC is readily detectable in both rats and mice [2,
3]. Because the appearance of STC in the serum coin-
cides with a massive up-regulation in ovarian STC gene
expression, the circulating hormone is believed to orig-
inate in the ovaries. In support of this notion, Western
blot analysis has recently shown that this circulating STC
is an 84 kD variant, identical in size to the smallest of
three big STC variants that are synthesized and secreted
by ovarian theca cells [3].
Big STC is produced however by only a few select
organs; steroidogenic cells in the ovaries and adrenal
glands [4, 5]. The other form of STC which is perhaps
better known is the 50 kD disulfide-linked homodimer
and structural homologue of fish STC [6]. Recently des-
ignated as STC50 to distinguish it from big STC, it also
appears to be the more widely distributed form of the hor-
mone. STC50 is abundant in tissues such as liver, kidney,
lung, and spleen, and the experimental evidence to date
suggests that it likely functions locally in each of these
organ systems as a paracrine mediator [7]. The analysis
of STC50 clearance kinetics has shown that a 100 lg hor-
mone bolus becomes nondetectable by radioimmunoas-
say within minutes of injection into male and female rats.
On the other hand, when the same analysis is conducted
with radiolabeled tracer, STC50 has values of distribution
(T1/2a; 1 minute) and clearance (T1/2b ; 60 minutes) that
are typical for a polypeptide hormone [1]. These findings
led us to conclude that STC50 was being rapidly metab-
olized after entering the serum to the extent that it was
being rendered nonimmunoreactive, and that the slower
clearing tracer was likely fragmented hormone. At the
time, this seemed to be a plausible means of eliminat-
ing from the circulation what was believed to be a purely
paracrine mediator. However, one intriguing observation
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that was not examined in greater detail was the extent to
which the tracer hormone was bound up and then re-
leased by red blood cells. In fact, the dissociation curve
for 125I-STC50 from the red blood cell fraction mirrored
that of its disappearance from the plasma [1], suggest-
ing that red blood cells were perhaps capable of binding
and releasing STC50 in accordance with prevailing tracer
levels.
Another facet of STC50 physiology that has so far de-
fied explanation relates to the liver. Northern blot anal-
ysis has revealed that liver tissue has very low levels of
STC gene expression. This is true in the case of both em-
bryos and adults [8, 9]. And yet, for a tissue with such
a low level of endogenous gene expression, immuno-
cytochemistry and Western blot analysis indicates that
hepatocytes contain surprisingly high levels of STC50,
most of which is in the mitochondrial fraction [1]. Simi-
larly, hepatocyte membranes and mitochondria both con-
tain relatively high levels of saturable, high-affinity (KD
0.2 nmol/L) STC receptors [7]. Collectively, these data
suggest that hepatic STC50 may not in fact be locally de-
rived, but is perhaps instead transported there via the
circulation. The purpose of this study therefore is to ad-
dress the hypothesis that there is STC carrying capacity
within the elements that constitute whole blood, which
could account for its unusual abundance in organs such
as the liver.
METHODS
Receptor binding studies on red blood cell ghosts
Red blood cell ghosts were isolated from dog, pig,
and human whole blood using an established protocol
[10]. Heparinized, fresh whole blood was centrifuged at
2000 × g for 10 minutes to pellet the red blood cells.
The red blood cell pellet was then subjected to two 5-
minute washes in phosphate-buffered saline (PBS), pH
7.6. Washed red blood cells were lysed with a hypotonic
buffer (5 mmol/L sodium phosphate, pH 8.0). The result-
ing ghosts were pelleted by centrifugation at 27,000 × g
and washed extensively in lysis buffer prior to use in re-
ceptor binding assays.
Saturation binding assays were carried out on purified
red cell ghosts to obtain estimates of KD and Bmax. These
assays were performed as previously described [7, 11],
using a fusion protein of STC and human placental alka-
line phosphatase as the experimental ligand (STC·AP)
and human placental alkaline phosphatase (AP) as the
control ligand, both of which were expressed in Madin-
Darby canine kidney (MDCK) cells [7]. The binding as-
say has previously been employed to characterize STC
receptors on microsomal membranes, mitochondria, nu-
clei, and lipid droplets from a variety of tissue types [3,
5, 7, 11]. Purified red cell ghosts were incubated in in-
creasing concentrations of STC·AP or AP dissolved in
Hanks’ balanced salt solution (HBSS) containing 0.1%
bovine serum albumin (BSA), pH 7.5, for 90 minutes at
room temperature. To separate the bound and free lig-
and, samples were centrifuged for 2 minutes at 13,000
× g. The pellets were subsequently washed three times
in HBSS containing 0.1% BSA, pH 7.5 (HBHA buffer),
lysed, and heat-treated to destroy endogenous AP activ-
ity. An AP detection buffer was then added to all samples
for the quantification of AP activity by spectrophotom-
etry. Specific binding was determined by subtracting the
AP activity in the ghosts incubated with AP alone from
those incubated with STC·AP. By taking into account the
specific activity of the STC·AP ligand, the data were then
converted into units of STC for calculation of KD and
Bmax.
Immunocytochemistry and in situ ligand binding studies
To localize STC and its receptor on red blood cells
at the histologic level, immunocytochemical and in situ
ligand binding studies were carried out on 5 micron tissue
sections of mouse embryonic kidney and heart. Tissues
were dissected from timed pregnant CD-1 mice, fixed by
immersion in PBS containing 4% paraformaldehyde, and
embedded in paraffin for sectioning.
Immunocytochemistry was performed on embryonic
day 14.5 (E14.5) mouse kidney as previously described
using a specific antiserum generated in rabbits against hu-
man recombinant STC50 (hSTC50) [1, 2]. Following an
overnight incubation in primary antiserum (1:1000), the
slides were washed extensively and the sites of antibody
binding were visualized with biotinylated secondary an-
tibodies and the Vectastain ABC peroxidase detection
system (Vector Laboratories, Burlingame, CA, USA).
Sections were subsequently counterstained with hema-
toxylin, dehydrated, and mounted.
In situ ligand binding was performed on E16.5 mouse
heart and perfusion-fixed, adult mouse kidney [12] in an
attempt to localize STC receptors and/or binding activ-
ity at the histologic level. The method has been previ-
ously characterized for specificity [7, 11] and employs
the same STC·AP fusion protein and AP control pro-
tein as described above. The technique has been suc-
cessfully used to localize STC receptors at the histologic
levels in liver, kidney, ovary, and mammary gland [3, 7,
11]. Fixed, paraffin-embedded tissue sections were equi-
librated in HBHA buffer and then incubated for 90 min-
utes in HBHA buffer containing 1 nmol/L STC·AP. Con-
trol slides were incubated in either AP alone or STC·AP
containing 1 lmol/L rhSTC. Slides were then washed and
processed for visualization of bound AP activity.
RESULTS
Receptor binding studies on red blood cells
The results of the receptor binding studies on human
female red cell ghosts are shown in Figure 1. Figure 1A
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Fig. 1. Saturation binding assay on human red blood cell ghosts. Red
blood cell ghosts were isolated from human blood (female) as described
in the Methods section. The binding assay was performed using a fu-
sion protein of stanniocalcin (STC) and human placental alkaline phos-
phatase (AP) as the experimental ligand (STC·AP) and human placen-
tal AP as the control ligand. (A) The raw binding data obtained with
STC·AP and AP. (B) Specific STC·AP binding after transformation of
the data. This assay yielded an estimated KD of 0.2 ± 0.05 nmol/L and
a Bmaxof 45.5 ± 2.3 pmol/mg protein (mean ± SEM).
shows the raw binding data obtained with STC·AP and
AP, whereas Figure 1B shows specific STC·AP binding af-
ter transformation of the data. The results of this satura-
tion binding assay yielded a KD of 0.22 ± 0.05 nmol/L and
a Bmax of 45.5 ± 2.3 pmol/mg protein. A second estimate
on the same sample yielded similar results (KD of 0.63 ±
0.1 nmol/L and a Bmax of 58.6 ± 5.2 pmol/mg protein).
The results obtained with pig and dog red cell ghosts also
revealed the presence of saturable, high-affinity binding
sites. However, the estimates of KD for nonprimate mam-
mals were significantly higher than those obtained in hu-
mans. Saturation binding analysis of red cell ghosts from
three male pigs yielded KD and Bmaxestimates of 17 ±
2.2 nmol/L and 75 ± 5.1 pmol/mg protein, respectively
(mean ± SEM) (N = 3). Similarly, binding studies on
red cells from a single male dog specimen yielded a KD
of 9.2 ± 1.2 nmol/L and a Bmax of 118 ± 10.8 pmol/mg
Table 1. Stanniocalcin (STC) binding characteristics of mammalian
red blood cellsa
Species KD nmol/L Bmaxpmol/mg protein
Human 0.2 ± 0.05 45.5 ± 2.3
Pig 17 ± 2.2 75 ± 5.1
Dog 9.2 ± 1.2 118 ± 10.8
aThe data are represented as the mean ± SEM.
protein. These receptor binding results have been sum-
marized in Table 1.
Immunocytochemistry and in situ ligand binding studies
The results of the histologic analysis are shown in
Figure 2. Figure 2A shows the results obtained follow-
ing in situ ligand binding. The panel shows a field of red
blood cells within the ventricle of E16.5 mouse heart.
Intense binding is evident over a subpopulation of red
blood cells (red arrows), comprising ∼10% of the cells
within the field of view. In contrast, little or no binding is
apparent to the remaining cells. Strong ligand binding is
also evident over the ventricular trabeculae of the devel-
oping heart (black arrows). Ligand binding to the subset
of red blood cells was specific to STC·AP as no staining
was apparent when AP was used as the control ligand (in-
set, upper right). These findings therefore extended the
receptor binding studies in Figure 1 by revealing that the
ability to bind STC was confined to just a subset of red
cells.
A similar proportion of red blood cells were positively
stained for the presence of STC ligand. Figure 2B illus-
trates the immunocytochemical staining results obtained
in E14.5 mouse kidney. The red arrow points to a group
of red blood cells confined within a vein, a subfraction
of which were intensely stained by the antiserum; others
were weakly stained, and the remainder were unstained.
These finding lent support to the in situ ligand binding
results in Figure 2A, and collectively implied that a small
fraction of the cells were positive for both ligand and
ligand binding activity. The developing proximal tubules
and collecting ducts also exhibited intense staining for
STC as previously described [8]. Staining of an adjacent
tissue section with antiserum preabsorbed overnight with
STC (1 lg/mL) produced no staining of either the red
blood cells or kidney tubules, thus demonstrating the
specificity of the reaction (inset, upper right).
The presence of soluble STC binding activity in shown
in Figure 2C, which is a low magnification image of the
adult mouse kidney cortex following in situ ligand bind-
ing with STC·AP fusion protein (the kidney capsule is
marked with a black arrow). A number of structures
have been labeled in the image, including the collecting
ducts and the distal convoluted tubules (red asterisks),
both of which exhibit an intense, punctate cellular pat-
tern of staining. Previous studies have shown that this






Fig. 2. In situ ligand binding and immunocytochemistry. (A) In situ localization of stanniocalcin (STC) binding sites on red blood cells in embryonic
day 14.5 (E14.5) mouse heart. Intense binding is evident to a sub-population of red blood cells (red arrows). Strong ligand binding is also evident
to the ventricular trabeculae (black arrows). Ligand binding was specific to STC·alkaline phosphatase (STC AP) as no staining was apparent when
AP was used as the control ligand (inset, upper right). (B) Immunocytochemical localization of STC on red blood cells in E16.5 mouse kidney. The
arrow points to a group of red blood cells, some of which are intensely stained; others are weakly stained or unstained. The developing proximal
tubules and collecting ducts are also stained. Staining of an adjacent section with antiserum preabsorbed with STC produced no staining (inset,
upper right). (C) In situ localization of STC binding activity in glomerular filtrate. Intense binding activity is evident around each glomerulus (G)
in the region encompassed by Bowman’s space that contains glomerular filtrate. Binding activity is also present in the lumen of some proximal
convoluted tubules (red arrows). The collecting ducts (CD) and the distal convoluted tubules (red asterisks) also exhibited intense, punctate cellular
staining. The use of AP as a ligand produced no specific staining (inset, lower left). (D) In situ localization of STC binding activity in the glomerulus.
This higher magnification image shows that the majority of ligand binding activity was associated with the glomerular filtrate in Bowman’s space
and not Bowman’s capsule, the glomerular capillaries or the mesangial cells. Proximal convoluted tubules (PCT) exhibited a sparser pattern of
punctate staining. The inset shows intense STC binding activity within a proximal convoluted tubule lumen. (E) In situ localization of STC binding
sites on proximal straight tubule luminal cell membranes (red arrows). The use of AP as a ligand produced no specific staining (not shown). The
calibration bar equals 50 microns in all panels.
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punctate staining is indicative of mitochondrial STC re-
ceptors within individual tubule cells [7]. In contrast, the
majority of proximal convoluted tubules are only weakly
stained. More important, however, is the intense binding
activity that is associated with individual glomeruli, many
of which are in evidence in Figure 2C. The ligand binding
to the glomerulus was by far the most intense within the
kidney and had the appearance of solid black staining de-
posits. Moreover, as the higher magnification of a single
glomerulus in Figure 2D shows, this ligand binding activ-
ity was associated entirely with the fluid-filled Bowman’s
space, where the glomerular filtrate forms and collects
prior to entering the nephron tubule. In contrast, there
was no binding activity in evidence over the glomerular
capillaries, associated mesangial cells, or for that matter,
Bowman’s capsule. It is also important to point out here
that STC binding activity was not necessarily present in all
glomeruli, and that in some specimens none was detected.
However, we have repeatedly observed this phenomenon
in both rat and mouse kidney.
Clues as to the fate of the soluble STC binding activ-
ity are apparent in Figure 2C and D. The red arrows in
Figure 2C highlight two proximal convoluted tubules in
which binding activity is visibly evident within the tubule
lumen. A higher magnification image has been inset in
Figure 2D showing the intense binding activity that is as-
sociated with the luminal filtrate and luminal brush bor-
der of individual tubule cells. These findings are indicative
of the passage of this soluble binding activity through the
nephron. However, none of this binding activity is evident
in the most distal nephron segments shown in Figure 2C;
namely the distal convoluted tubules (asterisks) and col-
lecting ducts. The possible reason for this is illustrated
in Figure 2E, which shows a field of proximal straight
tubules (S3 segment) near the cortical-medullary junc-
tion. In these tubule segments from both rats and mice,
intense ligand binding was found to be associated strictly
with the luminal cell membranes. As such, these findings
were indicative of a reabsorptive mechanism whereby the
soluble binding activity was being taken up by S3 seg-
ment tubular cells. Of further significance in this respect,
we have obtained no evidence of filtrate binding activ-
ity in any nephron segments downstream of the proximal
straight tubules (loop of Henle, thick ascending limb, etc.)
in either rats or mice.
DISCUSSION
The results of the present study have revealed that
mammalian red blood cells have significant carrying ca-
pacity for the hormone STC. In humans and domestic
mammals we have obtained unequivocal evidence for the
presence of high-affinity STC binding sites on purified red
blood cell membranes. In humans, the values obtained
for KD were not unlike those obtained for membrane-
associated STC receptors from rodent liver and kidney
[7]. In contrast, the estimates of KD obtained in domes-
tic animals were at least tenfold higher, but it remains
to be seen if this has physiologic significance. What may
be physiologically significant, however, is that the capac-
ity for STC binding was appreciably higher on red blood
cells than most other tissues that have been examined to
date. For instance, liver, kidney, ovary, and adrenal mem-
branes [5, 7, 11] have binding capacities in the low pico-
mole range (1 to 10 pmol/mg protein). The lone exception
is the adipocyte, which has a sixfold greater membrane
binding capacity than that observed in most other cells
(64 pmol/mg) and extraordinarily high receptor levels on
the lipid droplet membrane (1200 pmol/mg), where both
STC and its receptor are heavily sequestered [5]. Hence,
fat cell membranes approximate red blood cells in terms
of binding capacity for STC.
The high binding capacity of red blood cells could be
reflective of a specific role in the transport of STC to
tissues that would otherwise have no access to the hor-
mone. There is in fact a precedent for this in the case of
growth hormone, which is instead sequestered inside the
erythrocyte. This has been viewed as either a means of re-
moving abnormally high levels of growth hormone from
the serum or of delivering growth hormone to cells pe-
ripheral to its site of synthesis [13]. Two examples where
the latter scenario could certainly apply in the case of STC
are liver hepatocytes and fat cells, both of which contain
STC receptors and readily detectable levels of cellular
STC, but very low levels of endogenous STC produc-
tion [5, 9, 14]. Red blood cells also possess receptors for
insulin, insulin-like growth factor-1 (IGF-1), prolactin,
transforming growth factor-b (TGF-b), and leukemia in-
hibitory factor, to name only some [15–19], and their
purpose can vary. In the case of insulin, ligand binding
activates a Na+/Mg2+ exchanger to increase the levels of
Mg2+ within the cells [17]. As such, we should not rule out
the possibility that similar mechanisms might be opera-
tive in the case of STC and red blood cell ion transport,
especially in view of its well-known role as regulator of
transepithelial calcium and phosphate transport in kid-
ney and gut [6, 20].
The discovery of specific binding within the glomeru-
lar filtrate adds an entirely new dimension to our current
concept of STC signaling. It implies that a soluble binding
protein circulates in mammalian blood and is freely fil-
tered by the kidneys. Given the molecular weight cut-off
within the glomerular capillaries, its overall mass would
have to be no greater than ∼70 kD. The data further
suggest that following its filtration, the binding protein
passes through the proximal convoluted tubules and is
then completely reabsorbed by the proximal straight seg-
ment. Here it is presumably metabolized by tubular cells.
One unresolved aspect of the glomerular filtrate binding
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activity, however, is that it was not observed in all of the
kidneys which were examined, male or female. There-
fore, the physiologic conditions that lead to its presence
need to be established. It would also appear that the lig-
and accompanies the binding protein during the filtration
process, as subsequent studies have revealed that on occa-
sions when the glomerular filtrate does contain STC bind-
ing activity, it also contains visible STC immunoreactivity
as revealed by immunocytochemistry (unpublished ob-
servations). Therefore, the soluble binding protein could
be a means of clearing STC from the serum.
Collectively, our findings provide plausible explana-
tions as to why STC is generally undetectable in mam-
malian serum and why bolus injections of STC50 become
undetectable by immunoassay so soon thereafter [1]. In
light of the present findings it would now appear that
in both circumstances, much of the hormone is likely
sequestered by binding proteins that mask all antibody
epitopes. As such, these findings now raise several impor-
tant questions, one of which relates to the types of STC-1
(STC50 and big STC) that are bound by these proteins
under normal physiologic conditions. Given that the lig-
and used in our binding studies was a fusion protein of
STC50 and AP they can obviously bind STC50. However,
it remains to be seen if big STC [4] can also bind with
the same high affinity. A second question posed by these
findings is whether or not the binding capacity within red
blood cells is subject to regulation under conditions such
as pregnancy and lactation, when STC (the big STC vari-
ant) is detectable in the serum by radioimmunoassay [2].
During pregnancy and lactation, large quantities of big
STC are delivered to and sequestered by the mammary
glands via the bloodstream [3]. Thus, it is possible that the
soluble and/or tethered forms of the binding protein are
down-regulated at this time to allow for systemic deliv-
ery of the hormone. Finally, although the binding protein
on red blood cells may very well represent a mechanism
for delivering STC to distant targets, it is equally possi-
ble that the soluble form is a mechanism for removing
unwanted hormone from the circulation, albeit via renal
clearance as opposed to endothelial cell sequestration, as
has proven to be the case for the atrial natriuretic factor
clearance receptor [21].
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